Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inno8 Meal Timings PK Study in Healthy Participants
NCT07238816Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Nov 2025
- Primary completion
- May 2026
- Modality
- Nanobodies (VHH)
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of Inno 8 in hemophilia A (4 arms), sponsored by Novo Nordisk. Primary endpoint: Area under the plasma concentration-time curve from time 0 to infinity at Day 17. Started Nov 2025; status: completed.
02
Drugs
Inno 8
03
Conditions
hemophilia A
Beyond the preview
Go deeper on NCT07238816.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07238816.